Delivery Order W81XWH16D0009-W81XWH20F0253
- Not listed
- This $806,303.37 cost-plus-fixed-fee delivery order contract was awarded by the Department of the Army Medical Command to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for other direct costs and does not have a set-aside designation. Inbios International specializes in the design, development, and manufacture of immunodiagnostic devices, and has received over $85 million in prime contract awards from agencies like...
- This federal contract award to Inbios International Inc., a minority-owned business based in Seattle, Washington, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The $749,998 firm fixed-price contract supports research and development (R&D) of an antibody diagnostic for COVID-19. The contract was issued under a Broad Agency Announcement (BAA) solicitation from ASPR's Division of...
- The U.S. Department of Health and Human Services, specifically the Office of the Assistant Secretary for Preparedness and Response, awarded a $20,736,000 firm-fixed-price definitive contract to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the delivery of over-the-counter COVID-19 tests. The performance period is from September 20, 2023, to March 19, 2025. This contract has no set-aside designation, indicating...
- This is a $12,670,301.06 firm fixed-price definitive contract awarded by the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) to Inbios International, Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the production capacity expansion of COVID-19 diagnostic tests and was awarded under Contracting Opportunity FA7013-20-S-0002, which did not have a set-aside designation....
- This federal contract award by the Centers for Disease Control and Prevention (CDC) is for the procurement of ELISA detection kits from Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, valued at $85,485.00, is a firm fixed-price purchase order with an ultimate completion date of April 30, 2020. Inbios is a critical partner to the government, particularly during the COVID-19 pandemic, having secured numerous contracts with...
- The Department of State Bureau of East Asian and Pacific Affairs awarded a firm fixed-price purchase order to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington, for $143,218.00. The contract is for the supply of CDC 7553.0/ELISA detection kits, which are immunodiagnostic devices used for infectious disease testing. Inbios has a history of federal contract awards and grants related to the development and manufacture of diagnostic tests,...
- This federal contract award, valued at $4,708.00, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Inbios International Inc., a minority-owned biotechnology company based in Seattle, Washington. The contract is for the procurement of "TEST KIT,VISCERAL L" and has a completion date of June 24, 2024. Inbios International Inc. is a veteran-owned, for-profit organization that specializes in the design, development, and manufacture of immunodiagnostic...
- This federal contract award, HHSD2002017M93163P, was made by the Centers for Disease Control and Prevention (CDC) to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The $198,492.00 firm fixed-price purchase order is for INBIOS EQUIPMENT, with an ultimate completion date of July 14, 2017. The contract was awarded on March 9, 2017, and was not set aside for any specific business type. Inbios International is a key partner to multiple...
- This is a federal contract award to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, awarded by the Medical Command (MEDCOM) agency of the U.S. Department of Defense, is for ICT (Information and Communications Technology) development on a Cost-Plus-Fixed-Fee (CPFF) basis. The contract has a ceiling value of $1,724,742.02 and an ultimate completion date of September 18, 2019. The contract is not set-aside and was awarded...
- This is a federal contract award to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, awarded by the U.S. Army Medical Command (MEDCOM), is for a Small Business Innovation Research (SBIR) Phase II project, valued at $891,867.91. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, and the ultimate completion date is January 14, 2020. Inbios International Inc. is a specialized manufacturer of...
- W81XWH16D0009Indefinite Delivery Contract
- W81XWH16D0009-W81XWH20F0253Delivery Order
The Defense Health Agency awarded a $25.7 million cost-plus-fixed-fee delivery order to Inbios International Inc., a minority-owned biotechnology company headquartered in Seattle, Washington. The contract, issued on June 15, 2020, supports COVID-19 diagnostic development efforts through FDA Emergency Use Authorization antigen detection optimization and fast-track serology assay advancement. The work will be performed in Seattle and is scheduled for completion by May 31, 2025. This delivery order includes contractor-acquired property and government-furnished equipment provisions and was awarded without a set-aside designation. Inbios International specializes in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and has served as a critical partner to multiple federal agencies throughout the COVID-19 pandemic. The company's expertise in rapid diagnostic testing and previous contract experience with the Department of Defense, Department of Health and Human Services, Centers for Disease Control and Prevention, and Defense Logistics Agency positioned it to support this urgent pandemic response initiative. The contract reflects the government's prioritized efforts to accelerate diagnostic capability development during the early stages of the COVID-19 emergency response.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Development of multiple immunochromatographic test (ICTs) for the rapid diagnosis/detection of infectious diseases (IDs), and biological warfare agent (BWA) related IDs of military significance. | W81XWH-15-R-0014 | Department of the Army Medical Command | Award Notice 1/1 | 11/20/14, 3:09 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00015 | Other Administrative Action | $0 | 9/22/25 | |
| P00014 | Supplemental Agreement for work within scope | $9.8m | 5/8/24 | |
| P00013 | Supplemental Agreement for work within scope | ($10m) | 5/2/24 | |
| P00012 | Supplemental Agreement for work within scope | $420.0k | 3/1/24 | |
| P00011 | Funding Only Action | ($420k) | 2/16/24 |